GO:0043754 dihydrolipoamide branched chain acyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043754 describes the catalytic activity of the E2 subunit (dihydrolipoamide branched chain acyltransferase, also called BCE2 or DBT) within the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH).
• The enzyme transfers 2-methylpropanoyl, 3-methylbutanoyl, and S-2-methylbutanoyl groups from CoA thioesters to a lipoyl-lysine residue on the E2 protein, forming acyl-dihydrolipoamide intermediates.
• This activity is essential for the oxidative decarboxylation of branched-chain amino acids (leucine, isoleucine, valine) and is therefore central to energy metabolism and nitrogen handling.
• Deficiency in the BCKDH complex, including mutations in the E2 subunit, causes maple syrup urine disease (MSUD), a severe neurometabolic disorder.
• The E2 subunit forms a 24-mer core with octagonal symmetry in plants, and similar large multimeric assemblies are found in other organisms.
• Research models include zebrafish and mouse knockouts that recapitulate motor dysfunction and metabolic hallmarks of MSUD, enabling mechanistic and therapeutic studies.
Description
Dihydrolipoamide branched chain acyltransferase activity (GO:0043754) is a molecular function that catalyzes the transfer of acyl groups from branched-chain acyl-CoA thioesters to a lipoyl-lysine residue on the same enzyme, forming an acyl-dihydrolipoamide intermediate. This activity is a critical step in the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), which irreversibly decarboxylates the alpha-ketoacids derived from leucine, isoleucine, and valine. The enzyme is often referred to as E2 or dihydrolipoamide acyltransferase (BCE2 in plants, DBT in humans) and forms the core of the multienzyme complex. Because BCKDH is the rate-limiting step in branched-chain amino acid catabolism, its dysfunction leads to accumulation of branched-chain amino acids and their ketoacids, causing maple syrup urine disease (MSUD). Understanding GO:0043754 is therefore essential for researchers studying inborn errors of metabolism, mitochondrial energy homeostasis, and potential therapeutic targets. The activity has also been implicated in autoimmunity, as antimitochondrial antibodies in primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit BCKDH function. Moreover, in Mycobacterium tuberculosis, dihydrolipoamide acyltransferase is critical for pathogenesis, highlighting its broader biological importance.
dihydrolipoamide branched chain acyltransferase activity At A Glance
| GO ID | GO:0043754 |
|---|---|
| GO term | dihydrolipoamide branched chain acyltransferase activity |
| Ontology | molecular_function |
| Synonym | dihydrolipoamide branched chain transacylase activity; dihydrolipoyl transacylase activity; 2-methylpropanoyl-CoA:enzyme-6-N-(dihydrolipoyl)lysine:S-(2-methylpropanoyl)transferase activity |
| Major function | Catalyzes the transfer of branched-chain acyl groups from CoA thioesters to a lipoyl-lysine residue on the enzyme, forming an acyl-dihydrolipoamide intermediate within the BCKDH complex. |
| Reaction direction | Transfer of 2-methylpropanoyl, 3-methylbutanoyl, or S-2-methylbutanoyl groups from acyl-CoA to dihydrolipoamide. |
| Substrates | N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] and 2-methylpropanoyl-CoA (or other branched-chain acyl-CoAs). |
| Products | N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[protein] and CoA. |
| Complex context | Component of the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), which also includes E1 (branched-chain alpha-ketoacid decarboxylase) and E3 (dihydrolipoamide dehydrogenase). |
| Cellular location | Mitochondrial matrix. |
| Related disease | Maple syrup urine disease (MSUD) due to mutations in BCKDH subunits including E2. |
What Is GO:0043754?
In simple terms, GO:0043754 describes an enzymatic activity that moves a branched-chain acyl group from a CoA carrier to a lipoamide handle on a protein. The official definition states: Catalysis of the reaction: N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + 2-methylpropanoyl-CoA = N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[protein] + CoA. In addition to transferring the 2-methylpropanoyl group when acting on the oxoacid corresponding with valine, this activity also transfers the 3-methylbutanoyl and S-2-methylbutanoyl groups when acting on the oxo acids corresponding with leucine and isoleucine. This activity is synonymous with dihydrolipoamide branched chain transacylase, dihydrolipoyl transacylase, and several other names reflecting its role in acyl transfer.
Why Is dihydrolipoamide branched chain acyltransferase activity Important in Cell Biology?
GO:0043754 is essential for the catabolism of branched-chain amino acids, which are critical for energy production, nitrogen disposal, and neurotransmitter synthesis. Dysregulation of this activity leads to maple syrup urine disease, a devastating neurometabolic disorder characterized by accumulation of leucine, isoleucine, valine, and their ketoacids, causing neurotoxicity and motor dysfunction. The enzyme is also a target of autoantibodies in primary biliary cirrhosis, linking it to autoimmune liver disease. In pathogens like Mycobacterium tuberculosis, dihydrolipoamide acyltransferase is required for full virulence, making it a potential antimicrobial target. Thus, understanding GO:0043754 has broad implications for inherited metabolic diseases, autoimmunity, and infectious disease research.
• Central to branched-chain amino acid catabolism and mitochondrial energy production.
• Mutations cause maple syrup urine disease (MSUD), a severe neurometabolic disorder.
• Autoantibodies against dihydrolipoamide acyltransferase are found in primary biliary cirrhosis and inhibit enzyme function.
• Required for Mycobacterium tuberculosis pathogenesis, suggesting a target for anti-tuberculosis drugs.
• Forms a large 24-mer core with octagonal symmetry in plants, providing a model for multienzyme complex assembly.
• Zebrafish and mouse models with E2 mutations recapitulate MSUD phenotypes, enabling translational research.
• The activity is a key node in metabolic reprogramming and may influence cancer cell metabolism.
• Potential biomarker for MSUD diagnosis and monitoring.
• Involved in the regulation of insulin sensitivity and metabolic homeostasis.
• Target for therapeutic strategies aimed at restoring BCKDH function in metabolic disorders.
What Happens During dihydrolipoamide branched chain acyltransferase activity?
Substrate recognition and acyl transfer
In simple terms: The enzyme grabs a branched-chain acyl group from a carrier molecule and attaches it to a flexible arm on itself.
The E2 subunit of the BCKDH complex recognizes branched-chain acyl-CoA thioesters, such as 2-methylpropanoyl-CoA (derived from valine), 3-methylbutanoyl-CoA (from leucine), and S-2-methylbutanoyl-CoA (from isoleucine). The enzyme catalyzes the transfer of these acyl groups to the lipoyl-lysine residue on its own dihydrolipoamide arm, forming an acyl-dihydrolipoamide intermediate. This reaction is essential for the subsequent oxidative decarboxylation steps in branched-chain amino acid catabolism.
Formation of the acyl-dihydrolipoamide intermediate
In simple terms: The acyl group is now tethered to the enzyme via a lipoamide swing arm, ready to be passed to the next enzyme in the complex.
The product of the transfer reaction is N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[protein], where the acyl group is covalently linked to the dihydrolipoamide moiety. This intermediate serves as a substrate for the E3 subunit (dihydrolipoamide dehydrogenase), which reoxidizes the dihydrolipoamide and releases the acyl group as a CoA thioester, completing the catalytic cycle. The lipoyl domain acts as a swinging arm that shuttles intermediates between active sites of the complex.
Role in the BCKDH complex
In simple terms: This enzyme is the core of a large molecular machine that breaks down branched-chain amino acids.
The E2 subunit forms the structural core of the BCKDH complex, which also includes E1 (branched-chain alpha-ketoacid decarboxylase) and E3 (dihydrolipoamide dehydrogenase). The complex catalyzes the irreversible oxidative decarboxylation of alpha-ketoacids derived from leucine, isoleucine, and valine, producing branched-chain acyl-CoA thioesters, NADH, and CO2. The E2 subunit's acyltransferase activity is central to this process, as it couples the decarboxylation step (E1) with the reoxidation step (E3).
Structural organization of the E2 core
In simple terms: Many copies of the enzyme assemble into a large, symmetric ball that provides multiple active sites.
In plants, the dihydrolipoyl acyltransferase (BCE2) subunit forms a 24-mer core with octagonal symmetry, as revealed by small-angle X-ray scattering and electron microscopy. This large multimeric assembly is characteristic of 2-oxoacid dehydrogenase complexes and provides a scaffold for the binding of E1 and E3 subunits. The symmetry and size of the core are critical for efficient substrate channeling and regulation of the complex.
Catalytic mechanism and cofactors
In simple terms: The enzyme uses a lipoamide cofactor to accept and transfer acyl groups in a two-step process.
The catalytic mechanism involves the reduction of the lipoamide disulfide by the acyl group, forming a covalent acyl-dihydrolipoamide intermediate. This step is followed by transfer of the acyl group to CoA, regenerating the oxidized lipoamide. The reaction requires no additional cofactors beyond the lipoyl-lysine residue, which is covalently attached to the E2 protein. The activity is dependent on the redox state of the lipoamide and the availability of acyl-CoA substrates.
Key Genes Involved in GO:0043754 dihydrolipoamide branched chain acyltransferase activity
The following genes encode proteins that either possess dihydrolipoamide branched chain acyltransferase activity or are essential components of the BCKDH complex and related pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DBT (BCKDHB) | Encodes the E2 subunit of BCKDH, which has dihydrolipoamide branched chain acyltransferase activity. | Mutations cause MSUD; target for gene therapy and metabolic studies. |
| BCKDHA | Encodes the E1 alpha subunit of BCKDH, which decarboxylates branched-chain alpha-ketoacids. | Mutations cause MSUD; interacts with E2 for substrate channeling. |
| BCKDHB | Encodes the E1 beta subunit of BCKDH. | Mutations cause MSUD; structural and functional studies. |
| DLD | Encodes the E3 subunit (dihydrolipoamide dehydrogenase) that reoxidizes the dihydrolipoamide arm. | Mutations cause E3 deficiency; linked to metabolic disorders. |
| BCKDK | Encodes a kinase that phosphorylates and inactivates BCKDH, regulating branched-chain amino acid catabolism. | Target for modulating BCKDH activity in metabolic diseases. |
| PPM1K | Encodes a phosphatase that activates BCKDH by dephosphorylation. | Regulates BCKDH activity; potential therapeutic target. |
| SLC7A5 | Transports branched-chain amino acids into cells, influencing substrate availability for BCKDH. | Linked to cancer metabolism and mTOR signaling. |
| SLC3A2 | Partner of SLC7A5 for amino acid transport. | Affects BCAA uptake and BCKDH flux. |
| BCAT1 | Branched-chain aminotransferase, converts BCAAs to alpha-ketoacids for BCKDH. | Overexpressed in cancers; metabolic reprogramming. |
| BCAT2 | Mitochondrial branched-chain aminotransferase. | Regulates BCAA catabolism; linked to insulin resistance. |
| IVD | Isovaleryl-CoA dehydrogenase, acts downstream of BCKDH in leucine catabolism. | Mutations cause isovaleric acidemia. |
| ACADSB | Short/branched chain acyl-CoA dehydrogenase, involved in isoleucine catabolism. | Defects cause 2-methylbutyryl-CoA dehydrogenase deficiency. |
| HADHA | Mitochondrial trifunctional protein, involved in fatty acid oxidation and interacts with BCKDH. | Mutations cause fatty acid oxidation disorders. |
| PPARGC1A | Transcriptional coactivator that regulates mitochondrial biogenesis and BCKDH expression. | Modulates metabolic flux and energy homeostasis. |
| SIRT3 | Mitochondrial deacetylase that may regulate BCKDH activity. | Links metabolism to aging and stress responses. |
| MTOR | Kinase that senses amino acids and regulates BCKDH via downstream signaling. | Central to cell growth and metabolic control. |
| MYC | Oncogene that reprograms metabolism, including BCAA catabolism. | Target in cancer metabolism research. |
How Is dihydrolipoamide branched chain acyltransferase activity Regulated?
The activity of dihydrolipoamide branched chain acyltransferase is regulated primarily through the phosphorylation state of the BCKDH complex. BCKDH kinase (BCKDK) phosphorylates the E1 subunit, inhibiting the entire complex, while protein phosphatase 2C (PPM1K) dephosphorylates and activates it. This reversible phosphorylation allows rapid adaptation to changes in branched-chain amino acid levels and energy status. Additionally, the expression of BCKDH subunits can be regulated at the transcriptional level by factors such as PPARGC1A and MYC, which influence mitochondrial biogenesis and metabolic reprogramming. The activity is also sensitive to the availability of its substrates and cofactors, including acyl-CoAs and NAD+.
dihydrolipoamide branched chain acyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DBT | Maple syrup urine disease (MSUD) | Zebrafish knockout, mouse knockout, patient-derived iPSCs |
| BCKDHA | MSUD | Mouse models, cell lines with point mutations |
| BCKDHB | MSUD | Knockout mice, enzymatic assays |
| DLD | E3 deficiency, metabolic disorders | Patient fibroblasts, knockout cell lines |
| BCKDK | MSUD-like phenotype, metabolic dysregulation | Knockout mice, overexpression models |
Maple Syrup Urine Disease (MSUD)
Mutations in the DBT gene, which encodes the E2 subunit with dihydrolipoamide branched chain acyltransferase activity, cause maple syrup urine disease (MSUD), an autosomal recessive disorder characterized by accumulation of branched-chain amino acids and their ketoacids. Patients present with neurological symptoms, poor feeding, and a characteristic sweet odor of urine. Zebrafish and mouse models with mutations in the E2 subunit recapitulate motor dysfunction and metabolic abnormalities, providing valuable systems for studying MSUD pathogenesis and testing therapies. Molecular studies in Chilean patients have identified various mutations in BCKDH genes, expanding the genotypic spectrum of MSUD.
Primary Biliary Cirrhosis (PBC)
Antimitochondrial antibodies in primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit the enzyme function of the branched-chain alpha-ketoacid dehydrogenase complex. This autoimmunity targets the E2 subunit, leading to impaired BCAA catabolism and contributing to the cholestatic liver disease. The peculiar autoimmunity of PBC involves multiple mitochondrial autoantigens, with the E2 subunit being a major target. Understanding this autoimmune response provides insights into the breakdown of immune tolerance and potential immunomodulatory therapies.
Tuberculosis
In Mycobacterium tuberculosis, dihydrolipoamide acyltransferase is critical for pathogenesis, as it is required for the assembly and function of the branched-chain ketoacid dehydrogenase complex. Deletion of the gene encoding this activity attenuates virulence in mouse models, suggesting that inhibitors of this enzyme could serve as novel anti-tuberculosis agents. This highlights the broader significance of GO:0043754 beyond human metabolism.
Cancer Metabolism
Altered branched-chain amino acid catabolism, including changes in BCKDH activity, is observed in various cancers. The E2 subunit and its regulatory kinases may influence tumor growth by modulating the availability of branched-chain amino acids for biosynthetic pathways. Targeting BCKDH activity is being explored as a metabolic strategy in cancer therapy.
From dihydrolipoamide branched chain acyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of DBT knockout on BCAA catabolism? | DBT knockout cell lines (e.g., HEK293, HepG2) |
| How do MSUD-associated point mutations affect enzyme activity? | Point mutation knock-in models (e.g., DBT R301H) |
| Can wild-type DBT rescue the metabolic phenotype? | Knock-in of tagged DBT for rescue experiments |
| What is the role of DBT overexpression in cancer metabolism? | DBT overexpression cell lines |
| How does DBT interact with other BCKDH subunits? | Knock-in of epitope-tagged DBT for co-IP |
| What are the downstream effects of DBT deficiency on neuronal function? | Zebrafish dbt mutant models |
How to Study the dihydrolipoamide branched chain acyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric assay | NADH production coupled to E3 activity | Kinetic analysis of E2 activity |
| Radioactive assay | Transfer of labeled acyl groups | Substrate specificity studies |
| Western blot | Protein expression and modification | Detection of E2 subunit in cells/tissues |
| Immunoprecipitation | Protein-protein interactions | Identification of BCKDH complex components |
| 13C metabolic flux | Flux through BCKDH | Metabolic reprogramming studies |
| SAXS/EM | Structural organization | Determination of 24-mer core symmetry |
| Metabolomics | BCAA and ketoacid levels | Diagnosis and monitoring of MSUD |
Enzymatic activity assays
Dihydrolipoamide branched chain acyltransferase activity can be measured using spectrophotometric assays that monitor the reduction of NAD+ to NADH at 340 nm, coupled to the E3 subunit. These assays typically use branched-chain acyl-CoA substrates and dihydrolipoamide as acceptor, and are useful for determining kinetic parameters and inhibitor effects. Alternatively, radioactive assays with labeled acyl-CoA can be employed.
Western blotting and immunoprecipitation
Western blotting with antibodies against the E2 subunit (DBT) can assess protein expression levels and post-translational modifications. Immunoprecipitation followed by mass spectrometry can identify interacting partners and post-translational modifications, such as phosphorylation and lipoylation. These methods are essential for studying the regulation and assembly of the BCKDH complex.
Metabolic flux analysis
Stable isotope tracing with 13C-labeled branched-chain amino acids can quantify flux through the BCKDH complex in cells and tissues. This approach reveals how genetic mutations or pharmacological interventions affect BCAA catabolism. Metabolomics profiling of plasma or urine can also detect accumulation of branched-chain amino acids and ketoacids in disease models.
Structural biology and biophysics
Small-angle X-ray scattering (SAXS) and electron microscopy have been used to determine the 24-mer core structure of the plant BCE2 subunit, revealing octagonal symmetry. These techniques provide insights into the assembly and conformational dynamics of the complex. Site-directed mutagenesis combined with activity assays can map catalytic residues and regulatory sites.
How CRISPR Can Be Used to Study GO:0043754 dihydrolipoamide branched chain acyltransferase activity
Knockout
CRISPR-Cas9 knockout of DBT (the gene encoding the E2 subunit) in cell lines such as HEK293 or HepG2 can abolish dihydrolipoamide branched chain acyltransferase activity, leading to accumulation of branched-chain amino acids and ketoacids. These knockout models are valuable for studying the metabolic consequences of BCKDH deficiency and for testing rescue strategies. Knockout zebrafish models of dbt exhibit motor dysfunction and recapitulate MSUD phenotypes.
Point Mutation
CRISPR-mediated knock-in of specific MSUD-associated point mutations (e.g., DBT R301H, identified in patients) allows precise modeling of disease-causing variants. These point mutation models can reveal how single amino acid changes affect enzyme activity, complex assembly, and substrate specificity. They are also useful for testing pharmacological chaperones or gene editing therapies.
Knock-in
Knock-in of epitope-tagged DBT (e.g., FLAG or HA) at the endogenous locus enables studies of protein localization, interactions, and dynamics without overexpression artifacts. Tagged knock-in models can be used for affinity purification of the BCKDH complex and for live-cell imaging. This approach is particularly useful for understanding the assembly of the 24-mer core.
Overexpression
Overexpression of wild-type or mutant DBT in cell lines can be achieved by lentiviral transduction or CRISPR activation (CRISPRa). Overexpression models are useful for studying the effects of increased enzyme activity on metabolic flux and for identifying downstream targets. They can also be used to test dominant-negative effects of mutant alleles.
How EDITGENE Supports dihydrolipoamide branched chain acyltransferase activity Research
Researchers studying dihydrolipoamide branched chain acyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic pathways, disease phenotypes, or drug responses. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for dihydrolipoamide branched chain acyltransferase activity research.
Frequently Asked Questions About dihydrolipoamide branched chain acyltransferase activity
What is dihydrolipoamide branched chain acyltransferase activity?
It is a molecular function (GO:0043754) that catalyzes the transfer of branched-chain acyl groups from CoA thioesters to a lipoyl-lysine residue on the enzyme, forming an acyl-dihydrolipoamide intermediate within the BCKDH complex.
What genes are involved in dihydrolipoamide branched chain acyltransferase activity?
The primary gene is DBT (also known as BCKDHB), which encodes the E2 subunit. Other genes in the BCKDH complex include BCKDHA, BCKDHB, and DLD.
What diseases are associated with dihydrolipoamide branched chain acyltransferase activity?
Mutations in DBT cause maple syrup urine disease (MSUD). Autoantibodies against the enzyme are found in primary biliary cirrhosis, and the activity is important for Mycobacterium tuberculosis pathogenesis.
How is dihydrolipoamide branched chain acyltransferase activity regulated?
It is regulated by phosphorylation of the BCKDH complex by BCKDK (inhibitory) and dephosphorylation by PPM1K (activating). Transcriptional regulation also occurs via PPARGC1A and MYC.
What is the role of dihydrolipoamide branched chain acyltransferase in maple syrup urine disease?
Deficiency of this activity leads to accumulation of branched-chain amino acids and ketoacids, causing neurotoxicity and the characteristic symptoms of MSUD.
Can CRISPR be used to study dihydrolipoamide branched chain acyltransferase activity?
Yes, CRISPR knockout, point mutation knock-in, and tagged knock-in models of DBT and other BCKDH genes are powerful tools to study the enzyme's function and disease mechanisms.
What model organisms are used to study dihydrolipoamide branched chain acyltransferase activity?
Zebrafish and mouse models with mutations in the E2 subunit are widely used to recapitulate MSUD phenotypes and study motor dysfunction.
What is the structure of the dihydrolipoamide branched chain acyltransferase core?
In plants, the BCE2 subunit forms a 24-mer core with octagonal symmetry, as determined by SAXS and electron microscopy.
How is dihydrolipoamide branched chain acyltransferase activity measured?
It can be measured using spectrophotometric assays coupled to NADH production, radioactive assays with labeled acyl-CoA, or by monitoring metabolic flux with 13C-labeled substrates.
Why is dihydrolipoamide branched chain acyltransferase important for tuberculosis?
In Mycobacterium tuberculosis, the enzyme is critical for pathogenesis, and its deletion attenuates virulence, suggesting it as a potential drug target.
Conclusion
Dihydrolipoamide branched chain acyltransferase activity (GO:0043754) is a fundamental enzymatic function in branched-chain amino acid catabolism, with critical roles in human health and disease. Its dysfunction causes maple syrup urine disease, and it is implicated in autoimmunity and infectious disease. The availability of CRISPR models and advanced analytical methods provides unprecedented opportunities to dissect its mechanism and develop targeted therapies. EDITGENE offers a comprehensive suite of services to support research on this important activity.
References
- 1. Fregeau DR et al.. 1989. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex.. J Immunol 142(11):3815-20 PMID: 2715637
- 2. Chuang DT et al.. 2006. Lessons from genetic disorders of branched-chain amino acid metabolism.. J Nutr 136(1 Suppl):243S-9S PMID: 16365091
- 3. Friedrich T et al.. 2012. Mutation of zebrafish dihydrolipoamide branched-chain transacylase E2 results in motor dysfunction and models maple syrup urine disease.. Dis Model Mech 5(2):248-58 PMID: 22046030
- 4. Mooney BP et al.. 2000. The dihydrolipoyl acyltransferase (BCE2) subunit of the plant branched-chain alpha-ketoacid dehydrogenase complex forms a 24-mer core with octagonal symmetry.. Protein Sci 9(7):1334-9 PMID: 10933498
- 5. Campanholi DRR et al.. 2021. Molecular basis of various forms of maple syrup urine disease in Chilean patients.. Mol Genet Genomic Med 9(5):e1616 PMID: 33955723
- 6. Mackay IR et al.. 2000. The peculiar autoimmunity of primary biliary cirrhosis.. Immunol Rev 174:226-37 PMID: 10807519
- 7. Shi S et al.. 2006. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis.. Infect Immun 74(1):56-63 PMID: 16368957
- 8. Homanics GE et al.. 2006. Production and characterization of murine models of classic and intermediate maple syrup urine disease.. BMC Med Genet 7:33 PMID: 16579849
